In class II/III obesity cohorts, pooled GLP-1 drugs including liraglutide were associated with higher 2-year total costs than bariatric surgery ($63 483 [SE $1563] versus $51 794 [SE $1724]; P<.001).
In plain wordsIn class II or III obesity cohorts, pooled drugs including liraglutide were linked to higher 2-year costs than bariatric surgery.
- Peptide
- Liraglutide
- Outcome
- IncreaseTotal costs over 2 years
- Study
n = 30,458
- Comparator
- Metabolic bariatric surgery
- Outcome group
- Healthcare costs and utilization · Whole body
Measurements
- Cost standard error
- 1563 $
- GLP-1 pooled group
- Cost standard error
- 1724 $
- bariatric surgery
Source sentences
The mean (SE) total costs over 2 years were $63 483 ($1563) for GLP-1 RAs and $51 794 ($1724) for MBS (P < .001).
5 context sentences(design, population, supporting numbers)
This cohort study used data from the Highmark Health insurance claims database and the Allegheny Health Network electronic medical record in the US.
Participants were patients with class II or III obesity treated with either MBS or GLP-1 RAs who were enrolled in Highmark insurance for at least 6 months prior to index treatment and had follow-up data available for at least 12 months.
Using propensity score weighting, the populations were adjusted for differences in baseline spending, health care utilization, age, sex, comorbidities, and smoking status.
MBS (sleeve gastrectomy or gastric bypass) vs GLP-1 RAs (dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, or tirzepatide).
Analyses included 30 458 patients (mean [SD] age, 50 [11] years; 20 118 [66.1%] female), with 14 101 undergoing MBS (mean [SD] follow-up, 34 [16] months) and 16 357 receiving GLP-1 RAs (mean [SD] follow-up, 32 [17] months).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.